Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Gyre Therapeutics Inc. (GYRE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/11/2025: GYRE (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $20
1 Year Target Price $20
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 23.61% | Avg. Invested days 20 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 07/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 679.02M USD | Price to earnings Ratio 374.5 | 1Y Target Price 20 |
Price to earnings Ratio 374.5 | 1Y Target Price 20 | ||
Volume (30-day avg) 1 | Beta - | 52 Weeks Range 6.11 - 19.00 | Updated Date 07/13/2025 |
52 Weeks Range 6.11 - 19.00 | Updated Date 07/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.02 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 7.21% | Operating Margin (TTM) 10.31% |
Management Effectiveness
Return on Assets (TTM) 5.18% | Return on Equity (TTM) 12.12% |
Valuation
Trailing PE 374.5 | Forward PE - | Enterprise Value 650711904 | Price to Sales(TTM) 6.75 |
Enterprise Value 650711904 | Price to Sales(TTM) 6.75 | ||
Enterprise Value to Revenue 6.47 | Enterprise Value to EBITDA 53.61 | Shares Outstanding 90656600 | Shares Floating 19717013 |
Shares Outstanding 90656600 | Shares Floating 19717013 | ||
Percent Insiders 91.25 | Percent Institutions 2.99 |
Upturn AI SWOT
Gyre Therapeutics Inc.
Company Overview
History and Background
Gyre Therapeutics, Inc. focuses on developing and commercializing innovative therapies for liver diseases. The company's history reflects a commitment to addressing unmet medical needs in hepatology, with milestones including preclinical and clinical development of proprietary drug candidates.
Core Business Areas
- Liver Disease Therapeutics: Development and commercialization of therapies for non-alcoholic steatohepatitis (NASH) and other liver-related conditions.
Leadership and Structure
Specific leadership details and organizational structure are not readily available in provided context but generally include a CEO, CFO, research and development leadership, and a board of directors.
Top Products and Market Share
Key Offerings
- F351: Gyre Therapeutics' lead drug candidate, F351, is a small molecule therapeutic designed to target fibrosis in NASH. Market share data is currently unavailable as the product is in clinical development. Competitors include Madrigal Pharmaceuticals (MDGL) and Viking Therapeutics (VKTX) who are also in the NASH space.
Market Dynamics
Industry Overview
The liver disease therapeutics market, especially for NASH, is rapidly growing due to the increasing prevalence of obesity and diabetes globally.
Positioning
Gyre Therapeutics is positioning itself as a key player in the NASH therapeutics market with its F351 candidate, focusing on novel mechanisms of action.
Total Addressable Market (TAM)
The NASH market is projected to reach tens of billions of dollars. Gyre Therapeutics aims to capture a significant portion of this market with successful clinical development and commercialization of F351.
Upturn SWOT Analysis
Strengths
- Proprietary drug candidate targeting NASH
- Focus on fibrosis resolution
- Experienced management team (assumed)
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Dependence on successful clinical trials
- Currently no marketed products
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into other liver disease indications
- Positive clinical trial results
Threats
- Competition from other NASH therapeutics developers
- Regulatory hurdles
- Clinical trial failures
Competitors and Market Share
Key Competitors
- MDGL
- VKTX
- GILD
Competitive Landscape
Gyre Therapeutics competes with larger, more established pharmaceutical companies in the NASH market. Its advantage lies in its unique therapeutic approach.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data unavailable.
Future Projections: Future growth depends on the successful development and commercialization of F351 and is highly speculative at this point.
Recent Initiatives: Focus on advancing F351 through clinical trials.
Summary
Gyre Therapeutics is a development-stage company focused on innovative liver disease therapeutics, particularly NASH. Its success hinges on the clinical development of F351. The company faces significant competition and financial constraints but has the potential for substantial growth if its lead candidate proves effective. Keeping a close watch on Clinical Trial results will determine the company's success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings (unavailable)
- Industry Reports
Disclaimers:
This analysis is based on limited publicly available information and should not be considered financial advice. Market share data is estimated and subject to change. Please consult a financial professional before making investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Gyre Therapeutics Inc.
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2006-04-12 | CEO & Director Dr. Han Ying Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 579 | Website https://www.gyretx.com |
Full time employees 579 | Website https://www.gyretx.com | ||
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY, under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573 is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.